Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact

As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed to restore regulatory T-cell function and dampen neuroinflammation, through a pivotal stage of development in ALS.